Hung, Chien-Fu Xu, Xuequn Li, Linhong Ma, Ying Jin, Qiu Viley, Angelia Allen, Cornell Natarajan, Pachai Shivakumar, Rama Peshwa, Madhusudan V
...
Published in
Human gene therapy
CD19-targeted chimeric antigen receptor (CAR) engineered T/natural killer (NK)-cell therapies can result in durable clinical responses in B-cell malignancies. However, CAR-based immunotherapies have been much less successful in solid cancers, in part due to "on-target off-tumor" toxicity related to expression of target tumor antigens on normal tiss...
Abken, Hinrich
Published in
Human gene therapy
Adoptive therapy with chimeric antigen receptor (CAR) redirected T cells achieved lasting remissions in hematologic malignancies, even in terminal stages of the disease. Exploring CAR T cell therapy in the treatment of solid tumors has just begun, balancing efficacy versus toxicity in early phase trials. In contrast to leukemia/lymphoma, solid tumo...
Lähteenvuo, Johanna Ylä-Herttuala, Seppo
Published in
Human gene therapy
Many promising cardiovascular gene therapy approaches have failed to fulfill expectations in clinical trials. However, 20 years of research and method development has laid a solid groundwork for future therapies, and the need for new treatment options still exists. The safety of gene therapy has been established with various viral vectors, transgen...
Geyer, Antonia Taschauer, Alexander Alioglu, Fatih Anton, Martina Maier, Julia Drothler, Elisabeth Simlinger, Manuela Yavuz, Sümeyye Sami, Haider Ogris, Manfred
...
Published in
Human gene therapy
Local delivery of anticancer agents or gene therapeutics to lung tumors can circumvent side effects or accumulation in non-target organs, but accessibility via the alveolar side of the blood-air barrier remains challenging. Polyplexes based on plasmid and linear polyethylenimine (LPEI) transfect healthy lung tissue when applied intravenously (i.v.)...
Wang, Wei Guo, Hao Li, Hongyue Yan, Yongjia Wu, Chao Wang, Xiaodong He, Xianghui Zhao, Na
Published in
Human gene therapy
Interleukin 35 (IL-35) is a relatively newly identified cytokine required for the regulatory and suppressive functions of regulatory T cells(Treg), playing an important role in the prevention of autoimmune diseases. In this study, we used the MSCs as the gene-delivery vehicles for IL-35 gene therapy and investigated their protective effects in Con ...
Klöß, Stephan Oberschmidt, Olaf Morgan, Michael Dahlke, Julia Arseniev, Lubomir Huppert, Volker Granzin, Markus Gardlowski, Tanja Matthies, Nadine Soltenborn, Stephanie
...
Published in
Human gene therapy
The administration of ex vivo expanded natural killer (NK) cells as potential antitumor effector cells appears to be suitable for effector cell-based immunotherapies in high-risk cancer patients. However, good manufacturing practice (GMP)-compliant manufacturing of clinical-grade NK cells at sufficiently high numbers represents a great challenge. T...
Tan, Yaqian Lin, Yuan Li, Kai Xiao, Xiao Liang, Jiankai Cai, Jing Guo, Li Li, Chuntao Zhu, Wenbo Xing, Fan
...
Published in
Human gene therapy
Oncolytic virotherapy is a novel and intriguing treatment strategy for cancer therapy. However, the clinical potential of oncolytic virus as single agent is limited. M1 virus is a promising oncolytic virus that has been tested in preclinical studies. In this study, we investigated the effect of the combination use of M1 virus and Bcl-2 family inhib...
Flotte, Terence R
Published in
Human gene therapy
Yu, Songlin Yao, Yongchao Xiao, Hongkui Li, Jiaojiao Liu, Quan Yang, Yijun Adah, Dickson Lu, Junnan Zhao, Siting Qin, Li
...
Published in
Human gene therapy
Previous research has proven that disruption of either the CCR5 or the CXCR4 gene confers resistance to R5-tropic or X4-tropic human immunodeficiency virus type 1 (HIV-1) infection, respectively. However, the urgent need to ablate both of the co-receptors in individual post-thymic CD4+ T cells for dual protection remains. This study ablated the CCR...
Chen, Hai-Xu Xiang, Hang Xu, Wen-Huan Li, Ming Yuan, Jie Liu, Juan Sun, Wan-Jun Zhang, Rong Li, Jun Ren, Zhao-Qi
...
Published in
Human gene therapy
Radiation-induced lung injury (RILI) is a major clinical complication for radiotherapy in thoracic tumors. An immediate effect of lung irradiation is the generation of reactive oxygen that can produce oxidative damage to DNA, lipids, and proteins resulting in lung cell injury or death. Currently, the medical management of RILI remains supportive. T...
